Prognostic Significance of Serum Lactate Dehydrogenase in Saudi P
Journal of Clinical & Experimental Dermatology Research

Journal of Clinical & Experimental Dermatology Research
Open Access

ISSN: 2155-9554

+44 7868 792050

Research Article - (2016) Volume 7, Issue 2

Prognostic Significance of Serum Lactate Dehydrogenase in Saudi Patients with Mycosis Fungoides: A Retrospective Study of 47 Patients

Fahad Al Saif*
Department of Dermatology, College of Medicine, King Saud University, Riyadh, Saudi Arabia
*Corresponding Author: Fahad Al Saif, Consultant Dermatologist, Department of Dermatology, College of Medicine, King Saud University, P.O. Box 7805, Riyadh 11472, Saudi Arabia, Tel: +966-11-4691426, Fax: +966-11-4691432 Email:


Background: Mycosis fungoides (MF) is the most common cutaneous T-cell lymphoma and its advanced-stage (MF; stage IIB to IV)) has aggressive behavior. Lactate dehydrogenase (LDH) has been demonstrated to correlate with progression of malignancy specially lymphoma and leukemia. The LDH level is expected to be useful clinical tool for evaluating the progression of MF.

Objective: This study aimed to evaluate the pretreatment LDH as a prognostic factor in Saudi patients with Mycosis fungoides.

Methods: We designed a retrospective study using biopsy-based data collected from 1997 to 2015 at King Khalid University Hospital. The correlation of LDH levels with clinical stages of Mycosis fungoides was studied.

Results: Of the 47 MF patients, there were 25 male and 22 female patients for a male: female ratio of 1.4:1. The mean patient age was 39 years; 87.2% (n=31) had limited stage of MF and 12.8 (n=6) had an advanced stage >IIA. There were 13 patients with a raised LDH at the time of diagnosis. All stage IA patients had normal LDH levels while stage IB, IIA and advanced stage had 20%, 50% and 100% elevated LDH, respectively.

Conclusions: Our results suggest that high LDH level may be used as an independent prognostic factor to measure the progression of Mycosis fungoides.


Keywords: Cutaneous T-cell lymphoma; LDH; mycosis fungoides; Saudi


Mycosis fungoides (MF) is a common type of cutaneous T-cell lymphoma with an indolent clinical course and a low risk of mortality in early disease. The Tumor-Nodes-Metastasis-Blood (TNMB) staging of mycosis fungoides (Table 1) is an important prognostic factor in MF and patients with Stage IA, IIB and IIA disease have “limited-stage” disease. The overall survival in these patients is good. In contrast, patients with stage 11B and higher usually have “advanced-stage” disease with aggressive behavior and worse prognosis [1].Other risk factors for survival in MF are male sex and older age, elevated lactate dehydrogenase (LDH), and histologic features of folliculotropism (FT) and large-cell transformation [1,2].

stage T N M B
IA 1 0 0 0,1
IB 2 0 0 0,1
II 1,2 1,2 0 0,1
IIB 3 0-2 0 0,1
III 4 0-2 0 0,1
IIIA 4 0-2 0 0
IIIB 4 0-2 0 1
IVA1 01-Apr 0-2 0 2
IVA2 01-Apr 3 0 0-2
IVB 01-Apr 0-3 1 0-2

Table 1: ISCL/EORTC revision to the staging of mycosis fungoides Source: ISLC/EORTC (2007) [14].

Lactate dehydrogenase (LDH) is a cytoplasmic enzyme that is widely expressed in tissues. LDH is an enzyme that catalyzes the conversion of lactate to pyruvate the last step of glycolysis. The pyruvate transformation to lactate is increased in malignancies which lead to tumor microenvironment acidification by which tumors control their own blood supply via vascular morphogenesis and finally promote tumor progression and metastasis [3]. High serum lactate dehydrogenase has been documented as a poor prognostic indicator in malignant lymphoma, pancreatic carcinoma, colorectal cancer and consider one important factor in staging and progression of melanoma [4-9]. In MF, routine blood analyses are of limited value. LDH is a nonspecific marker of tumor burden but associated with poor prognosis in MF [10]. There is less data available on the serum level of LDH as a marker of disease activity and progression in Saudi patients with MF. The aim of this retrospective study was to investigate the serum LDH in different stages of Mycosis fungoides.


The patient record system at the Department of Dermatology in King Khalid University hospital was used to identify all patients who had been diagnosed with MF based on clinical and histopathology data from January 1997 to December 2015. Data collection was approved by IRB (number: E-16-1777). The exclusion criteria were any patient with disease that can increase LHD including malignancy (leukemia and systemic lymphoma), liver disease, IHD, renal impairments and any muscle injury. We only included patients who had serum LDH before starting treatment. The normal value range of LDH was 120–227 U/L for male patients and120–227 U/L for female patients. MF staging was made according to the European Organization of Research and Treatment of Cancer (EORTC).


There were 133 patients registered as having MF; 86 patients were excluded due to chronic diseases or lack of baseline LDH measurements. There were 47 patients with clinically and histologically verified MF included in the study (Table 2). Of these, 25 were males (57.5%) and 22 (42.5%) were females. Male: female ratio was 1.4:1.

No. Sex Age LDH level Stage of the disease
1 male 26 124 IA
2 male 32 126 IA
3 female 50 128.2 IB
4 female 28 131 IB
5 male 37 132 IB
6 male 36 144 IB
7 male 60 145 IB
8 female 21 146 IA
9 male 30 147 IA
10 male 50 147 IB
11 male 45 149 IA
12 female 49 154 IA
13 female 28 154 IB
14 male 64 156 IA
15 female 36 158 IB
16 female 36 165 IIA
17 male 50 167 IA
18 male 24 170 IA
19 male 69 169 IB
20 male 35 176 IA
21 female 30 179 IA
22 male 47 180 IB
23 female 60 180 IA
24 female 45 182 IB
25 male 44 188 IB
26 male 29 189 IA
27 male 58 189 IA
28 female 70 198* IB
29 male 86 203 IB
30 female 15 204 IB
31 female 15 209 IB
32 female 31 209 IA
33 female 52 216* IB
34 female 25 216 IIA
35 male 14 224 IIA
36 female 35 226 IB
37 male 13 231 IB
38 male 20 252 IIA
39 male 17 259 III
40 male 43 277 IIA
41 female 10 283 IB
42 male 57 296 III
43 male 49 318 IIA
44 female 24 420 III
45 female 34 460 III
46 male 34 547 III
47 male 71 1445 IV

Table 2: Demographic profile and basic data of 47patients with mycosis fungoides arranged according to LDH value.

The median age was 39 years (range was 10-86 years). At the time of diagnosis, 87.2% (n=31) had limited stage of MF, 31.9 % were stage IA, 42.5% had stage IB and 12.8 had stage IIA. There were 12.8% (n=6) with advanced stage (>IIA), and 13 patients had elevated LDH at the time of diagnosis. All stage IA patients had normal LDH level while stage IB, IIA and advanced stage had 20%, 50% and 100% raised of LDH, respectively (Figures 1 and 2).


Figure 1: Curve of increment of LDH according to stages of MF.


Figure 2: LDH frequency in different stages of MF.


Mycosis fungoides is the most common subtype of cutaneous T cell lymphoma characterized by low malignancy, chronic nature and slow progress [1]. The peak age at presentation is around 55 to 60 years with a 2:1 male:female ratio [1,11,12]. The median age at initial diagnosis in our study was 39 years, which is lower than in those reported internationally but nearly equal to the median age of Saudi and Iranian patients [13,14]. On the other hand, we should consider the effects of excluding MF patients with chronic diseases that usually occurred in old age in explanation of early age of onset. The M:F ratio was 1.4:1, which is lower than previously reported for Saudi patients [13].

Olsen et al. published the staging of MF and Sézary syndrome (SS) as a result of the International Society for Cutaneous Lymphomas (ISCL) - European Organization of Research and Treatment of Cancer (EORTC) discussions considering cellular and molecular biology and diagnostic methods [15,16]. In our study, the stage at diagnosis showed that 87.2% (n=31) had limited stage of MF-31.9 % were in stage IA, 42.5% were stage IB, 12.8 were stage IIA, and 12.8 (n=6) were advanced stage >IIA. These results are compatible with results reported in the literatures [17]. Staging is still the most important prognostic factor and guides management of this complex disease.

Elevated LDH is significantly associated with a worse survival [18]. It has been widely acknowledged that elevated LDH is associated with unfavorable prognosis for different types of lymphoma [19-21]. In our study, there was a significant correlation between high LDH and advanced stages of MF (Figure 1). We found that 100% of patients with advanced stage had high LDH. An elevated serum LDH level at the time of diagnosis may supplement clinical judgment in detecting the high-risk group.

Limitations of the study

A key limitation of this study was the small number of patients, which led to relatively low statistical power. Further prospective studies with much larger patient populations are needed to clarify this association.

In conclusion, higher LDH level at the time of diagnosis was implicated in aggressive MF. This simple, inexpensive, and routinely measured marker may be an independent prognostic factor.


  1. Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, et al. (2010) Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: Validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J ClinOncol 28: 4730-4739
  2. Zackheim HS, Amin S, Kashani-Sabet M, McMillan A (1999) Prognosis in cutaneous T-cell lymphoma by skin stage. J Am AcadDermatol. 40:418-425.
  3. Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4 :891-899.
  4. Graeber GM, Clagett GP, Wolf RE, Cafferty PJ, Harmon JW, et al. (1990) Alterations in serum creatine kinase and lactate dehydrogenase. Association with abdominal aortic surgery, myocardial infarction and bowel necrosis. Chest 97:521-527.
  5. Kato GJ, McGowan V, Machado RF, Little JA, Taylor J 6th, et al. (2006) Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 107:2279–2285.
  6. Eigentler TK, Figl A, Krex D, Mohr P, Mauch C, et al. (2011) Dermatologic Cooperative Oncology Group and the National Interdisciplinary Working Group on Melanoma: Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer 117:1697–1703.
  7. Ferraris AM, Giuntini P, Gaetani GF (1979) Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin lymphomas. Blood 54: 928- 932.
  8. Schneider RJ, Seibert K, Passe S, Little C, Gee T, et al. (1980) Prognostic significance of serum lactate dehydrogenase in malignant lymphoma. Cancer 46: 139-143
  9. Flanagan NG, Ridway JC, Platt CC, Rowlands AJ, Whitson A (1989) Lactic dehydrogenase estimation in haematological malignancies. Clin Lab Haematol 11:17-26.
  10. Vidulich kA, Talpur R, Bassett RL, Duvic M (2009) Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. Int J Dermatol 48: 243-252.
  11. Criscione V D, Weinstock M A (2007) Incidence of cutaneous T-cell lymphoma in the United States, 1973–2002. Archives of Dermatology 143: 854-859.
  12. Quaglino P, Pimpinelli N, Berti E, Calzavara-Pinton P, Alfonso Lombardo G, et al. (2012)Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Ita- lian Group of Cutaneous Lymphomas. Cancer 118: 5830-5839.
  13. AlGhamdi KM, Arafah MM, Al-Mubarak LA, Khachemoune A, Al-Saif FM (2012) Profile of mycosis fungoides in 43 Saudi patients. Ann Saudi Med 32:283-287.
  14. Naeini FF, Abtahi-Naeini B, Sadeghiyan H, Nilforoushzadeh MA, Najafian J, Pourazizi M (2015) Mycosis Fungoides in Iranian population: An epidemiological and clinicopathological study. J Skin Cancer :306543
  15. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, et al. (2007) Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society of Cutaneous Lymphoma (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC) Blood. 110: 1713-1722.
  16. Yamashita T, Abbade LP, Marques ME, Marques SA (2012) Mycosis fungoides and Sézary syndrome: Clinical, histopathological and immunohistochemical review and update. An Bras Dermatol 87:817-828.
  17. Eklund Y, Aronsson A, Schmidtchen A, Relander T. (2016) Mycosis Fungoides: A retrospective study of 44 Swedish cases. ActaDermVenereol
  18. Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, et al. (2015) Cutaneous lymphoma international consortium study of outcome in advanced stages of Mycosis Fungoides and Sézary Syndrome: Effect of specific prognostic markers on survival and development of a prognostic model. J ClinOncol 33:3766-3773.
  19. WANZHUO X,Hu K, Xu F, Zhou D, Huang W, et al. (2013) Significance of clinical factors as prognostic indicators for patients with peripheral T-cell non-Hodgkin lymphoma: A retrospective analysis of 252 cases. MolClinOncol 1:911-917.
  20. Gallamini A1, Stelitano C, Calvi R, Bellei M, Mattei D, et al. (2004) Peripheral T-cell lymphoma unspecified (PTCL-U): A new prognostic model from a retrospective multicentricclinical study. Blood 103:2474–2479.
  21. A predictive model for aggressive non-Hodgkin’s lymphoma (1993) The international Non-Hodgkin’s Lymphoma prognostic factors project. N Engl J Med 329:987–994.
Citation: Saif FA (2016) Prognostic Significance of Serum Lactate Dehydrogenase in Saudi Patients with Mycosis Fungoides: A Retrospective Study of 47 Patients. J Clin Exp Dermatol Res 7:342.

Copyright: © 2016 Saif AF. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.